Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027627 (metastases)
 103,950 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The levels of PHI are evaluated in 94 patients, who are classified by histological, scintigraphycal, radiological, biochemical and clinical test in: 16 patients, who suffer from some premalignant lesions of breast and uterus, 15 patients, who suffer from cancer of breast without metastases, 20 patients who suffer from cancer of breast with metastases, 18 patients who suffer from with cancer of uterus without metastases, 25 patients who suffer from cancer of uterus with metastases. The PHI activity is also evaluated in relation to the activity of other enzymes (LDH, AIP, G-GT). It has been revealed that: a) the PHI activity keeps within limits of normal value in patients who suffer from some pre-malignant lesions; b) all the patients suffer from cancer of breast without metastases show normal levels of PHI; c) in the patients with cancer of breast with metastases: 5 patients show normal levels of PHI, 5 patients show levels of PHI within limits, certainly 10 patients show pathological levels; d) in patients with cancer of uterus without metastases the value of enzymes results pathological in 6 patients, 6 patients show levels of PHI within limits that are above average and 6 patients show normal levels of PHI; e) the value of PHI always results high in patients with cancer of uterus with metastases.
Quad Sclavo Diagn 1978 Sep
PMID:[The determination of phosphohexose isomerase in patients with cancer of breast and uterus. A comparison with other tests (author's transl)]. 3 46

Multiple endocrine neoplasia (MEN) type I is a genetically inherited disorder which predominantly involves the parathyroid and pituitary glands and pancreatic islets. Symptoms relevant to each endocrine gland may be present individually or in combination, since the tumours or hyperplasia can occur either synchronously or alone. Measurement of plasma hormone levels, endocrine function tests and radiological examination are necessary to make the diagnosis. Resection of the affected glands or treatment with specific pharmacotherapy is required for control of the disease. Long-term follow-up examination is vital to detect the appearance of lesions in other endocrine glands or the development of metastases. Screening of relatives and genetic counselling are important in the management of affected families.
S Afr Med J 1979 Sep 01
PMID:Multiple endocrine neoplasia: Part I. Wermer's syndrome. 4 54

The results of treatment of two groups of patients with primary melanoma are compared. 25 patients in group 1 were treated by wide local excision of the primary melanoma, and 23 in group 2 were treated by vaccination with live vaccinia virus 14 days before wide local excision. Vaccination exerts a favourable effect on the course of melanoma both in terms of survival and prolongation of the interval between treatment of the primary lesion and subsequent development of metastases.
Lancet 1975 Sep 27
PMID:Treatment of primary melanoma by intralesional vaccinia before excision. 5 9

Regan isoenzyme, variant alkaline phosphatase, and alpha-fetoprotein were found in the serum of a patient with gastric cancer. The histology of the tumor was tubular adenocarcinoma. There were metastases in the retroperitoneal lymph nodes, but not in the liver. The liver was normal microscopically, with no evidence of bile duct obstruction. alpha-Fetoprotein in the tumor tissue was detected by immunoprecipitation reaction in agar. Regan isoenzyme and variant alkaline phosphatase were also detected in the tumor tissue and total alkaline phosphatase activity of the tissue was very high. These findings suggested their tumor origin.
Gastroenterology 1976 Sep
PMID:Occurrence of alpha-fetoprotein, Regan isoenzyme, and variant alkaline phosphatase in the serum of a patient with gastric cancer. 5 76

The pyrimidine analog, 5-azacytidine (NSC 102816), was administered by continuous intravenous infusion in Ringer's lactate in increasing doses to sets of patients with metastatic cancer to establish a dose sufficient to produce mild toxicity. Twenty-one patients (23 trials) were treated with doses of 50-200 mg/sq/m/day for 5 days every 2-4 wk. Nausea and vomiting were moderate and easily preventable. Doses of 100-200 mg/sq/m for 5 days every 14 days produced granulocytopenia, usually after two courses. Less toxicity was observed when courses were given every 21-28 days. Forty-five patients with previously treated and refractory acute myeloblastic leukemia were treated. The majority received doses of 150 mg/sq m for 5 days every 2 wk. Eleven (24%) complete remissions and four partial remissions were observed. The number of courses to achieve remission averaged three and required an average of 59 days. Nine patients with blastic crisis of chronic myeloblastic leukemia and four with refractory acute lymphoblastic leukemia failed to respond. 5-Azacytidine administered by continuous infusion is well tolerated and is an active compound in acute myeloblastic leukemia.
Blood 1976 Sep
PMID:5-Azacytidine (NSC 102816): a new drug for the treatment of myeloblastic leukemia. 6 Jan 56

Increased tumor radiosensitivity can be achieved by the technique of synchronisation, although as yet this relationship has only been partial. Our clinical experiences from 1970-1974 with this technique lead to the following considerations: 1. Synchronized radiotherapy (Telecobalt) is administered twice weekly, independent of adjunctive medications (such as fluoro-uracil, vincristin or bleomycin). 2. Synchronized radiotherapy does not change previous indications for operative intervention. 3. The described technique permits successful treatment of advanced tumors as well as postoperative tumor recurrences of recurrences in previously-irradiated tisssues. 4. The radiosensitivity of poorly oxygenated tumor tissues may be increased. 5. Radiation dosage must not be reduced. 6. Distant tumor metastases can also be treated with additional chemotherapy (as synchronized chemotherapy).
HNO 1976 Sep
PMID:[Five-years synchronized radiotherapy in treatment of carcinoma of the head and neck: clinical results, 1970--1974 (author's transl)]. 6 Nov 94

"Fingerprints" of 0.9% NaCl solution extracts obtained from fetal guts and individual adenocarcinoma of the colon show a randomized pattern of expression of carcinoembryonic antigen (CEA) determinants by CEA radioimmunoassay and isoelectric focusing. All CEA-containing antigens found in a pool of 20 primary adenomas were found at some stage in fetal development. No single CEA-reacting peak was typical of any one period of fetal development. When fetal gut profiles were grouped according to trimester in utero, however, an expanded gene pool was found in the second trimester which correlates well with maximum gastrointestinal growth and differentiation. Isoelectric focusing-CEA radioimmunoassay profiles of individual primary adenomas were similar to but never identical with individual fetal gut profiles. "Fingerprints" of metastatic adenomas of entodermal origin showed quantitative and qualitative increases in molecules with CEA determinants unlike these latter categories. Such data suggest that both integrator and controller gene activities may be lost in metastatic disease. Rather than "phase-specific gene sets" on different chromosomes being activated by various oncogenic modalities, it is more probable that individual chromosomes are involved in oncogenesis. While more data are needed to confirm this idea, it is safe to say that the expression of molecules with CEA determinants need not be caused by either derepressive or reexpressive gene activation. These data point to the individuality of gene expression of molecules with CEA determinants both in fetal development and in early neoplasia. Since CEA-reacting molecules were not found in tumors of ectodermal or mesodermal origin by these methods, such products should be termed carcino-developmental antigens of entodermal or colonic origin.
Cancer Res 1976 Sep
PMID:Gene activation of molecules with carcinoembryonic antigen determinants in fetal development and in adenocarcinoma of the colon. 6 12

Bencyclane hydrogen fumarate (Fludilat) was tested on the stickiness of tumor cells in vivo and in vitro. It was intended to determine whether Fludilat reduced the cancer cell stickiness in vitro, and if the survival time of cancer cell carrying animals can be increased with Fludilat in vivo, or in combination with a cytostatic. For the in vitro trials, concentrations from 0.001 mg/ml to 1 mg/ml medium were chosen. The survival trial on NMRI-mice with Nemeth-Kellner lymphosarcoma was performed in three groups, each with 4-5 sub-groups: Control group--Fludilat 5 mg, 10 mg, 20 mg/kg bodyweight, Bleomycin--50 mg/kg bodyweight, 100 mg/kg bodyweight, 250 mg/kg bodyweight, Bleomycin 50 mg/kg bodyweight + Fludilat 5 mg/kg bodyweight, Bleomycin 100 mg/kg + Fludilat 10 mg/kg bodyweight, Bleomycin 250 mg/kg + Fludilat 20 mg/kg bodyweight. The sequence of deaths was determined, and the 50% survival time was taken as criterium for the effect of the treatment. The in vitro trials showed a complete removal of the monolayer of the tumor cells from the bottom of the culture flask, in doses of 0.01-1 mg/ml medium. In the in vivo trial an increase in the 50% survival time could be achieved in all groups. The results of combined therapy of Fludilat and Bleomycin were striking. In comparison to the control animals, the treated animals showed that the occurrence of solid abdominal metastases from the Nemeth-Kellner lymphosarcoma could be almost completely prevented, especially at high doses. The Ca++-antagonistic effect, in changing the surface of the cells, is discussed as a mechanism of action.
Fortschr Med 1976 Sep 16
PMID:[The effect of bencyclane hydrogen fumarate (Fludilate) on the adhesion of tumor cells in vivo and in vitro]. 6 34

The results of a percutaneous radiotherapy of 136 patients with bladder carcinomas who were treated between 1966 and 1972 are presented in a retrospective study. Before the beginning of the treatment, the diagnosis of these patients had been verified by a lympho-cavo-urography. 21% of the patients had a pathological lymphogram and 40% a pathological urogram. The survival time of patients with normal and those with pathological lympho-cavo-urography showed a difference which was statistically significant (p less than 0.001). There was no patient with inhibited urinary defluxion and demonstrated lymph node metastases who lived longer than 21 months after the treatment. Exclusive percutaneous radiotherapy and primary total cystectomy cannot be considered as curative therapeutic methods. If metastases in the lymph nodes of the regio iliaca communis and paraaortal are demonstrated by lymphography, the prognosis is unfavourable and only palliative methods are justified.
Strahlentherapie 1978 Sep
PMID:[Lymph node metastases and ureteral obstructions as prognostic parameters for the percutaneous radiotherapy of the bladder carcinoma (author's transl)]. 8 48

42 patients with metastatic breast carcinoma were treated with aminoglutethimide, which inhibits adrenal steroid hormone synthesis. Treatment was stopped in 2 patients before response could be assessed; of the other 40, 15 (37.5%) had an objective response, 1 (2.5%) showed a response in bone but not in soft tissue, and 4 (10%) had complete or very great relief of metastatic bone pain but no radiological evidence of improvement. 19 (53%) of 36 patients with bone metastases responded to treatment (15 had X-ray evidence and 4 had pain relief), as did 5 (45%) of 11 patients with soft tissue metastases, 2 (25%) of 8 with malignant marrow infiltration, 1 (14%) of 7 with lung metastases, and none of 13 with liver metastases. Response was commonest in patients who had previously responded to other forms of endocrine therapy. Side-effects, usually mild and transient, occurred in a few patients; the most important were an initial period of somnolence in 9 patients and a rash in 5.
Lancet 1978 Sep 23
PMID:Aminoglutethimide in treatment of metastatic breast carcinoma. 8 May 76


1 2 3 4 5 6 7 8 9 10 Next >>